Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website. The full press release is available at https://ibn.fm/1QdP7.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways that promote neuroplasticity. The company aims to address unmet needs in mental health, particularly for depression and anxiety. Its lead candidate, HLP003, is in Phase 3 clinical development as an adjunctive treatment for major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
The fireside chat at the Jefferies conference provides an opportunity for Helus Pharma to update investors on its clinical programs and strategic direction. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company’s website at www.helus.com. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
This announcement underscores Helus Pharma’s commitment to advancing mental health treatments and its engagement with the investment community. The company’s participation in a major healthcare conference signals its progress in bringing novel therapies to market.
